Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 Nov 5;2(6):e001469.
doi: 10.1136/bmjopen-2012-001469. Print 2012.

Clinical effectiveness of a patient decision aid to improve decision quality and glycaemic control in people with diabetes making treatment choices: a cluster randomised controlled trial (PANDAs) in general practice

Nigel Mathers  1 , Chirk Jenn Ng, Michael Joseph Campbell, Brigitte Colwell, Ian Brown, Alastair Bradley
Affiliations

Clinical effectiveness of a patient decision aid to improve decision quality and glycaemic control in people with diabetes making treatment choices: a cluster randomised controlled trial (PANDAs) in general practice

Nigel Mathers et al. BMJ Open. .

Abstract

Objective: To determine the effectiveness of a patient decision aid (PDA) to improve decision quality and glycaemic control in people with diabetes making treatment choices using a cluster randomised controlled trial (RCT).

Design: A cluster RCT.

Setting: 49 general practices in UK randomised into intervention (n=25) and control (n=24).

Participants: General practices Inclusion criteria: >4 medical partners; list size >7000; and a diabetes register with >1% of practice population. 191 practices assessed for eligibility, and 49 practices randomised and completed the study. Patients People with type 2 diabetes mellitus (T2DM) taking at least two oral glucose-lowering drugs with maximum tolerated dose with a glycosolated haemoglobin (HbA1c) greater than 7.4% (IFCC HbA1c >57 mmol/mol) or advised in the preceeding 6 months to add or consider changing to insulin therapy.

Exclusion criteria: currently using insulin therapy; difficulty reading or understanding English; difficulty in understanding the purpose of the study; visual or cognitive impairment or mentally ill. A total of 182 assessed for eligibility, 175 randomised to 95 intervention and 80 controls, and 167 completion and anlaysis.

Intervention: Brief training of clinicians and use of PDA with patients in single consultation.

Primary outcomes: Decision quality (Decisional Conflict Scores, knowledge, realistic expectations and autonomy) and glycaemic control (glycosolated haemoglobin, HbA1c).

Secondary outcomes: Knowledge and realistic expectations of the risks and benefits of insulin therapy and diabetic complications.

Results: Intervention group: lower total Decisional Conflict Scores (17.4 vs 25.2, p<0.001); better knowledge (51.6% vs 28.8%, p<0.001); realistic expectations (risk of 'hypo', 'weight gain', 'complications'; 81.0% vs 5.2%, 70.5% vs 5.3%, 26.3% vs 5.0% respectively, p<0.001); and were more autonomous in decision-making (64.1% vs 42.9%, p=0.012). No significant difference in the glycaemic control between the two groups.

Conclusions: Use of the PANDAs decision aid reduces decisional conflict, improves knowledge, promotes realistic expectations and autonomy in people with diabetes making treatment choices in general practice. ISRCTN TRIALS REGISTER NUMBER: 14842077.

PubMed Disclaimer

Figures

Figure 1
Figure 1
PANDAs postcard: an example of the viral marketing strategy to recruit practices.
Figure 2
Figure 2
PANDAs CONSORT flow diagram.
See this image and copyright information in PMC

References

    1. Diabetes UK. Diabetes in the UK 2011/2012: Key statistics on diabetes. http://www.diabetes.org.uk/Documents/Reports/Diabetes-in-the-UK-2011–12.pdf (accessed 12 Mar 2012)
    1. Diabetes.co.uk. Cost of Diabetes. http://www.diabetes.co.uk/cost-of-diabetes.html (accessed 12 Mar 2012)
    1. National Institute for Health and Clinical Excellence (NICE) Type 2 diabetes: newer agents. London: NICE, 2009 - PubMed
    1. UKPDS Group Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837–53 - PubMed
    1. Turner RC, Cull CA, Frighi V, et al. Glycemic control with diet, sulphonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). JAMA 1999;281:2005–12 - PubMed